PharmaVentures, the transaction advisory and media company, announced today the launch of its new product, PharmaDeals v2, a database of deals and alliances for the pharmaceuticals sector.
PharmaVentures announced today an agreement with Growthink Research, the U.S.-based market research firm, to distribute its Venture Capital database to customers in industry and academic institutions worldwide.
PharmaTelevision®, the authoritative channel for the pharmaceutical, biotechnology and related industries, today announced that it is teaming up with the EBD Group to offer delegates at BIO-Europe a Television Interview and Media Training.
Oxford, UK, October 21 2010: In the current BioPharma economic climate; with smaller companies desperately needing the right development partners for survival and larger ones needing to support their existing businesses through making the right deals, having the best, most comprehensive, intelligence and insights are absolutely essential for success.
Increasing demand for its services in the Asia-Pacific region has led PharmaVentures, a leading provider of specialist consultancy, advisory and intelligence services, to appoint Dr Robert Daniels as its dedicated Vice President for the region. Robert will be based in Sydney, Australia.
Oxford, UK, January 19th, 2012 - PharmaVentures announced today that it was delighted to act as transaction advisor to MSD (operating in the US and Canada as Merck & Co) to secure its deal with BioCity Scotland, a new joint venture between BioCity Nottingham and Roslin BioCentre, for the former MSD research facility in Newhouse, Lanarkshire.
Agreement for US sales of MoxDuo® IR to address the $2.5 billion acute pain market in 2012
Sydney, Australia and Bedminster, New Jersey – QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today execution of a binding Letter of Intent (LOI) with Actavis Inc. for the formation of a strategic partnership to commercialise MoxDuo IR in the US acute pain marketplace.
Mon 18 Jul 2011 : Vital Foods partners with Nestlé Health Science
Vital Foods today announced that Nestlé Health Science has become a strategic investor and taken a minority stake in the company. The terms of the transaction are not being disclosed.
PharmaVentures Client BergenBio entered into an agreement for Rigel's preclinical candidate, R428 (now referred to as BGB324), an Axl kinase inhibitor for oncology.
Oxford, UK. 01 March 2011 - PharmaVentures Ltd acted as exclusive advisor and broker to the global biopharma company, UCB in its successful strategic partnership with UK-based developer and manufacturer Aesica Pharmaceuticals.